Scarica l'app Stockscreener
11.13
3.34%
0.36
Dopo l'orario di chiusura:
11.13
Precedente Chiudi:
$10.77
Aprire:
$11
Volume 24 ore:
38,540
Relative Volume:
0.79
Capitalizzazione di mercato:
$1.91B
Reddito:
$549.97M
Utile/perdita netta:
$458.86M
Rapporto P/E:
4.2423
EPS:
2.6236
Flusso di cassa netto:
$-89.06M
1 W Prestazione:
+1.09%
1M Prestazione:
+3.44%
6M Prestazione:
-25.80%
1 anno Prestazione:
-37.40%
Intervallo 1D:
$10.90
$11.13
Intervallo di 1 settimana:
$10.62
$11.60
Portata 52W:
$9.77
$18.30
Hutchmed China Limited Adr Stock (HCM) Company Profile
Compare HCM vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
11.13 | 1.91B | 549.97M | 458.86M | -89.06M | 2.6236 |
TAK
Takeda Pharmaceutical Co Adr
|
17.10 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.855 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.01 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.28 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
517.71 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2025-05-13 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-11-24 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-05-04 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-08-03 | Iniziato | Jefferies | Buy |
| 2020-10-02 | Iniziato | Deutsche Bank | Buy |
| 2020-03-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-20 | Iniziato | Goldman | Buy |
| 2019-11-19 | Iniziato | CLSA | Buy |
| 2019-10-23 | Reiterato | BofA/Merrill | Buy |
| 2019-07-05 | Iniziato | Macquarie | Outperform |
Mostra tutto
Hutchmed China Limited Adr Borsa (HCM) Ultime notizie
A2AF74 Forecast — Price Target — Prediction for 2027 - TradingView
HUTCHMED (NASDAQ:HCM) Stock Price Down 6%Here's Why - MarketBeat
Price to sales forward of HUTCHMED (China) Limited Sponsored ADR – FWB:H7T1 - TradingView
HCM Stock Price, Quote & Chart - ChartMill
NMPA clears HUTCHMED (HCM) drug ORPATHYS for MET-amplified gastric cancer - Stock Titan
HUTCHMED Announces NMPA Approval for ORPATHYS® for the - GlobeNewswire
Price to book forward of HUTCHMED (China) Limited Sponsored ADR – LSE:0J7G - TradingView
HUTCHMED (NASDAQ: HCM) schedules 2026 half-year results and investor webcasts - Stock Titan
HUTCHMED to Announce 2026 Half-Year Financial Results - GlobeNewswire
HUTCHMED (HCM) details 2015 and 2026 share option blocklisting return - Stock Titan
REGHutchmed China LtdAnnouncement on blocklisting six monthly return - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LS:A2AF74) - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (GETTEX:H7T1) - TradingView
H7T1 Forecast — Price Target — Prediction for 2027 - TradingView
0J7G Forecast — Price Target — Prediction for 2027 - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LSX:A2AF74) - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (NASDAQ:HCM) - TradingView
Pivotal fanregratinib ICC data and China NDA review for HUTCHMED (NASDAQ: HCM) - Stock Titan
RCSHutchmed China LtdHUTCHMED Highlights Phase II Data at ESMO - TradingView
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib - GlobeNewswire
HUTCHMED analyst targets stay high, shares trade well below consensus - ad-hoc-news.de
HUTCHMED Announces Phase III China Data from ESLIM-02 Study of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia - aastocks.com
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress - GlobeNewswire Inc.
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in - GlobeNewswire
HUTCHMED (Nasdaq: HCM) files AIM block for 43,616,756 shares - Stock Titan
HCMHUTCHMED (China) Limited ADR Stock Price and Quote - Finviz
HUTCHMED (Nasdaq: HCM) showcases savolitinib, fruquintinib and surufatinib data at ASCO 2026 - Stock Titan
HUTCHMED: ELUNATE and TYVYT Combination Therapy Approved by NMPA for Advanced or Metastatic Renal Cell Carcinoma - AASTOCKS.com
HUTCHMED to Present Multiple Study Data at ASCO Annual Meeting in US - AASTOCKS.com
New HUTCHMED (HCM) ELUNATE plus TYVYT approval targets second-line kidney cancer - Stock Titan
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting - GlobeNewswire
HUTCHMED (HCM) shareholders back all AGM votes including 2026 option scheme - Stock Titan
HUTCHMED (NASDAQ:HCM) Hits New 52-Week LowWhat's Next? - MarketBeat
HUTCHMED To Present Data at American Association of Cancer Research Annual Meeting 2026 - AASTOCKS.com
HUTCHMED (Nasdaq: HCM) reports 872,335,120 voting shares - Stock Titan
和黃醫藥(00013.HK)索樂匹尼布上市申請獲受理並納入優先審評 - AASTOCKS.com
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
HUTCHMED (Nasdaq: HCM) gains China priority review and breakthrough status for sovleplenib - Stock Titan
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference - Yahoo Finance
HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026 - The Manila Times
Hutchmed China (NASDAQ:HCM) Gains Attention Amid Healthcare Momentum - Kalkine Media
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Rating of "Hold" by Analysts - MarketBeat
Revenue per share of HUTCHMED (China) Limited Sponsored ADR – FWB:H7T1 - TradingView — Track All Markets
HUTCHMED (HCM) showcases ATTC and surufatinib study data at AACR 2026 - Stock Titan
HUTCHMED (HCM) plans 2026 AGM, 10% buyback mandate and 5% option pool - Stock Titan
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 - GlobeNewswire
HUTCHMED (LON:HCM) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance Singapore
Zai Lab Limited (ZLAB) stock price, news, quote and history - uk.finance.yahoo.com
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo Finance
Hutchmed China Limited Adr Azioni (HCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.08%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):